Monday, April 22, 2019

A Brief Look of Glycosylation

Glycosylation is the process by which a protein or lipid is attached to a sugar under the control of an enzyme, starting at the endoplasmic reticulum and ending at the Golgi apparatus. The sugar is transferred to the protein by the action of a glycosyltransferase, and the amino acid residue on the protein forms a glycosidic bond. The protein undergoes glycosylation to form glycoproteins. Glycosylation is an important modification of proteins and regulates protein function.

Process
N-linked sugar chain synthesis begins in the endoplasmic reticulum and is completed in the Golgi apparatus. The glycoprotein formed in the endoplasmic reticulum has a similar sugar chain. After the Cis surface enters the Golgi apparatus, a series of ordered processing and modification occurs during the transport between the membrane capsules. The original sugar chain is large. Part of the mannose is excised, but a variety of glycosyltransferases are sequentially added with different types of sugar molecules to form oligosaccharide chains with different structures. The spatial structure of the glycoprotein determines that it can bind to that glycosyltransferase and undergo specific glycosylation modifications.
Many glycoproteins have both N-linked sugar chains and O-linked sugar chains. O-linked glycosylation is carried out in the Golgi apparatus. Usually, the first attached sugar unit is N-acetylgalactose, and the linked sites are the hydroxyl groups of Ser, Thr and Hyp, and then the glycosyl groups are successively transferred to form. Oligosaccharide chains, sugar donors are also nucleoside sugars, such as UDP-galactose. The result of glycosylation allows different proteins to be labeled differently, altering the conformation of the polypeptide and increasing the stability of the protein.

One or more aminoglycan chains can also be attached to the serine residue of the core protein via xylose on the Golgi to form proteoglycans. Some of these proteins are secreted outside the cell to form an extracellular matrix or mucus layer, some anchored to the membrane.

Classification
According to the type of glycoside chain, protein glycosylation can be divided into four types, that is, the hydroxyl group of serine, threonine, hydroxylysine and hydroxyproline is used as a point of connection to form an -O-glycosidic bond. Using an amide group of asparagine, an α-amino group of an N-terminal amino acid, and an ω-amino group of lysine or arginine as a point of attachment to form an -N-glycosidic bond; aspartic acid or glutamic acid The free carboxyl group is a point of attachment, forming a lipotypic bond type and a glycopeptide bond with cysteine as a point of attachment.

Future prospects

Drug glycosylation is a unique post-translational modification, and their synthesis is not a model-driven process, so obtaining a consistent glycoform is a daunting task. It is known that glycoforms have a regulatory effect on a range of complex functions, and the strategy of the invention to easily monitor glycoforms in real time is pertinent. In addition to significant advances in process analysis, glycosylation level control remains an unrealized goal. The biopharmaceutical industry and academic researchers have worked hard to bridge this gap, and have made great progress in understanding the complexity of post-translational modifications, the effects of various process variables on glycoforms, and the effects of various glycan types on the efficacy of biopharmaceuticals. Have some understanding. This also clearly implies that in the development of biosimilar drugs, similar drug manufacturers cannot obtain research and development information related to the original drug.

Risk assessment based on biopharmaceutical CQA helps manufacturers make wise decisions early in drug development. In mAbs, the glycoform range as a mass attribute can be estimated by the effector function, half-life, immunogenicity, and pharmacokinetic/potency of the drug. For example, a fucose-free modification enhances ADCC activity, while sialylation affects the anti-inflammatory properties of mAb molecules. Therefore, based on the mechanism of action of the drug and our understanding of the biological role of different glycan species, biosimilar drug manufacturers can make decisions based on data early in the development process. This will significantly reduce the risk of late clinical trial failure and increase our trust in comparability analysis.

Therefore, the use of powerful analytical instruments allows real-time analysis and monitoring of glycosylation modifications, such as NMR using a single amino acid resolution combined with advanced statistical tools to analyze protein characteristics. In addition, mathematical models will be a powerful tool for predicting real-time glycosylation levels in the near future, and can be used to adjust the ongoing culture process in situ based on culture parameters. With the advent of system biology in cell culture, factors such as kinetic parameters, metabolic constants, and cell viability parameters can be easily established. Biosimilars are a valuable and affordable alternative to existing biologics, and powerful instruments and tools have a significant impact on the emergence of biosimilars.

Services related to glycosylation

An Overview of Human Leukocyte Antigen(HLA)

HLA (human leukocyte antigen) is the expression product of human major histocompatibility complex (MHC Tetramer), which is the most complex polymorphic system known in the human body. Since the discovery of Jean Dausset's first HLA antigen in 1958, by the 1970s, HLA has become an important emerging field of research in immunogenetics, immunobiology and biochemistry. Now, the composition, structure and function of its system have been basically clarified, and its physical and chemical properties and biological effects have been clarified. These research results not only have important theoretical significance, but also have great biomedical value.

Nature and structure
HLA is a highly polymorphic allogeneic antigen whose chemical nature is a glycoprotein composed of an alpha heavy chain (glycosylated) and a beta light chain non-covalently bound. The amino terminus of the peptide chain is outward (about 3/4 of the entire molecule), the carboxyl terminus penetrates into the cytoplasm, and the intermediate hydrophobic portion is in the cell membrane. HLA is classified into class I antigens and class II antigens according to their distribution and function.

Genetic control
HLA is a gene cluster encoding the major histocompatibility complex (MHC) of humans. HLA is located on the short arm of chromosome 6.

The specificity of the HLAI-like antigen depends on the alpha heavy chain and is encoded by the HLA-A, B, and C sites; its beta light chain is β2-microglobulin, and the coding gene is on chromosome 15. The HLA class II antigen is controlled by the HLA-D region (including 5 sub-regions), and the A gene and the B gene are encoded by the α heavy chain and the β light chain, respectively, and the antigen polymorphism depends on the β light chain. Each of the above genes (named WHO nomenclature committee revised in 1975) is a polymorphic site (reciprocal) and codominant. If MHC is viewed as a whole, its polymorphism is more prominent. It is conservatively estimated that there are at least 1300 different haplotypes, correspondingly about 17 x 10 seven-squares genotype. This is the genetic basis of almost no HLA except for the identical twins, so that HLA can be regarded as an individual's "identity card."

Biological functions
Target function

HLAI-like antigens are distributed in all nucleated cells. Its antigen specificity lies in the specific amino acid sequence of the peptide chain epitope. These antigens can be altered by foreign substances such as certain viruses or chemicals. When these gene products are altered, they become autoimmune and become targets for immune exclusion. It can be seen that the essence of the target function is to "recognize the self" to ensure the integrity of the body. Therefore, it is important to distribute all cells and their polymorphisms.

Identification function
The recognition function of HLA refers to the unique synergy in the immune response. Antibodies are produced in B cells, but in most cases, macrophages and T lymphocytes are required to participate. The process is: after the antigen is processed by the macrophage, the antigen information is transmitted to the T helper cell, and the latter transmits the information to the B cell, so that the B cell further differentiates to generate a specific antibody. In this process, T helper cells not only recognize antigens on sensitized macrophages, but also recognize whether macrophages are consistent with their own class II antigens. That is to say, only when the haplotype of the macrophage and the haplotype of the T helper cell are identical, the T helper cell is activated, so that the immune response is carried out under strict genetic control.

Medical value
Organ transplantation

The HLA study was originally carried out under the auspices of organ transplantation research.

Therefore, HLA is also called transplant antigen. Clinical practice has shown that rejection of allogeneic transplants (except for identical twins) should be the biggest obstacle to success. In genetics, MHC is transmitted as a unit of Mendelian. Therefore, there may be three cases in which HLAs are identical, semi-identical, and different. Practice has proved that more than 90% of the kidney transplants of the same sibling donors with HLA have a good effect; the donors with different haplotypes have a significant effect; those with different phenotypes rarely survive. The revealing of the nature and function of HLA provides an important theoretical basis for transplantation matching. It can be said that organ transplantation is an important achievement in contemporary medicine.

A genetic marker for certain diseases
In 1972, Russel first reported that patients with psoriasis (psoriasis) carry HLA-B13 or HLA-B17. Since then, a large number of other diseases have been found to be associated with specific HLA. Among them, HLA-B27 antigen is found in about 90% of patients with ankylosing spondylitis, so that HLA typing has diagnostic value, and even the disease subtype can be confirmed earlier. Clinical differences, for example, psoriasis vulgaris is associated with HLA, whereas pustular psoriasis is not; juvenile insulin-dependent diabetes mellitus is associated with HLA-B8, HLA-Bw15, and HLA-B18, and late-onset diabetes There is no such correlation. Therefore, certain types of HLA are the genetic markers of certain diseases. For example, autosomal recessive adrenal hyperplasia is due to a lack of 21-hydroxylase. HLA antigen polymorphism was used for population association analysis and family linkage analysis. It was found that two hydroxylase sites (21-OHA and 21-OHB) were closely linked to HLA-B and DR. Accordingly, prenatal diagnosis can be made using HLA. In eugenics, the relative risk of a child's illness can be estimated for certain diseases based on available data. On the other hand, the relationship between HLA and longevity also forms a research hotspot.

Forensic
Because of its high polymorphism, HLA is the most representative genetic marker that is representative of individual specificity and is associated with the life of the individual. The HLA type has the same probability of being identical among the unrelated individuals. Forensic medicine uses HLA genotype or phenotype detection for individual identification to "identify the body", and because of its haplotype genetic characteristics, it is also an important means of paternity testing.

High resolution technology
With the development of medicine, such as leukemia, thalassemia, etc. can be typed and tested with the latest genetic technology, and then find a suitable donor for transplantation. At present, HLA high-resolution peripheral blood stem cell transplantation technology can greatly improve the matching effect, making the patient's recovery faster and more assured.

The latest HLA high-resolution typing technology makes it possible to establish a high-resolution HLA database, which not only helps to find suitable donors quickly and accurately, but also greatly improves the utilization rate of the bone marrow bank, making it better for patients, and can be HLA. Scientific research and technological innovation provide basic data support.

Other related service:

Sunday, April 21, 2019

Disease Model and Gene Therapy for Transgenic Animals

Animal models of disease model diseases in transgenic animals have contributed to the development of medicine. However, many diseases are difficult to manufacture animal models by artificially induced methods, or many diseases do not occur in experimental animals or only in higher mammals, so it is difficult to obtain animal models by spontaneous or artificial directed cultivation. The emergence of transgenic technology has made it possible for humans to accurately study the relationship between genes and diseases, and can use any individual to analyze the genetic function in each stage of individual occurrence. Therefore, the development of animal models of transgenic diseases has become a hot spot for transgenic animals, and some have entered the application stage.

Virus model
(1) Poliovirus receptor transgenic mice: Human poliovirus receptors were cloned and transgenic mice were made. The poliovirus cell line receptor gene (human PVR gene) was microinjected into early embryos of C57BL/10 mice to prepare transgenic mice and the finished product line. This mouse expresses a human receptor and has the susceptibility to poliovirus. Moreover, mice infected with this virus exhibit the same clinical symptoms as humans, and the specificity to the virus strain also exhibits the same properties as humans. Therefore, in addition to being a human disease model, this mouse may also be used as a substitute for monkeys for the determination of the efficacy and specificity of poliovirus, and has a wide range of uses.

(2) Hepatitis B virus carrier model: Hepatitis B virus (HBV) carriers have a liver cancer rate 100 to 200 times that of normal people, but there is still no effective treatment. HBV only infects humans or gorillas, and other suitable animal models have not yet been developed. It is generally believed that the immune response to HBV is genetically controlled, and the immune response is insufficient to become chronic hepatitis; the mechanism of liver cancer is not unique, and there are various problems in hepatocyte necrosis and regeneration caused by the presence of chronic hepatitis. Genetic variation and canceration. The HBV genome is a circular double-stranded DNA molecule containing a partially single-stranded region. The length of the two single strands is different, the long strand is the minus strand (3.2 kb), and the short strand is the positive strand, which is about 50% to 80% of the minus strand. . So if you make l. The DNA of 2HB-BS is a double-stranded linear DNA for transduction, enabling genome-wide expression. On the other hand, when only HBS antigen expression is required, only the 1.2HB-BS gene needs to be introduced. The HBV DNA to which l.2HB-BS was added was introduced into C57BL/6J mice, and HBV was replicated in the liver to release virions in the blood. Gene expression occurs during the embryonic phase, but exhibits immunopotentiation (passivation status) against these viral antigens, does not exhibit any pathological changes, and thus can be used as a model for human HBV carriers. The mice that lead the human gene have no abnormalities in clinical manifestations like humans.

(3) Hepatitis B surface antigen transgenic animal model: The human hepatitis B surface antigen (HBsAg) gene is introduced into a mouse, and a mouse HBsAg gene can be obtained, and HBsAg can be produced in the liver of the transgenic mouse. This transgenic mouse can simulate the patient's toxic state without causing disease. Chisari found that HBsAg-positive transgenic mice were immunized with HBsAg plus Freund's complete or incomplete adjuvant and were unable to induce specific antibodies, whereas HBsAg-negative transgenic mice responded with HBsAg-positive The transgenic mice did not show any pathological changes within 6 months, but showed a continuous poisoning state. The results of these tests indicate that hepatocyte damage in patients with hepatitis B is not directly caused by HBsAg expression, but is caused by an immune response to viral antigens on the membrane of liver cells. This transgenic mouse model can be used to study the relationship between immune response tolerance and hepatocyte injury, and to explore the pathogenesis, persistent toxic state and its clearance, drug screening experiments, HBV DNA replication, expression and regulation in the host and type B. The relationship between the onset of hepatitis and other issues related to HBV pathology and therapeutics.

In addition to the establishment of animal models of transgenic mice as described above, animal models of transgenic mice with other viral diseases have also been established. Transgenic mice obtained by injecting the JC virus genome can be used as a transgenic mouse animal model of progressive multifocal leukoencephalopathy (PML) using tyrosine aminotransferase of human T lymphocyte type 1 virus (HTLV-1). The transgenic mouse prepared by the (TAT) gene can be used as an animal model of a disease of human nerve fiber tendon.

Gene therapy
Gene therapy uses molecular biology techniques to introduce foreign genes into target cells to correct, compensate for gene defects or to inhibit and block the overexpression of abnormal genes, thereby achieving the goal of treating diseases. Gene therapy includes gene compensation, gene correction, cytokine gene import, antisense RNA technology, and the like. As a new means of treating diseases, this technology has developed extremely fast, and several cases have entered the clinical practical stage, solving the clinical problems that traditional methods cannot solve. This novel and unique treatment is also derived from the study of transgenic mice.
In the production of animal models for gene therapy, retroviruses are currently widely used as vectors to introduce foreign genes of interest. This recombinant antibody retrovirus can integrate the functional gene carried into the chromosome of the recipient cell, and the expression product of the introduced gene will make up for the original gene product. A mouse lacking growth hormone is usually smaller and male than the normal mouse. The growth hormone gene is introduced into the mouse, and the expression of the exogenous growth hormone gene can increase the number of A and murine individuals with the dwarf by a factor of three, and restore the male fertility; Mice with the major histocompatibility complex (MHC) gene have an immune response against synthetic anti-Ig, but MHC-transgenic mice can restore immune response; mice with beta thalassemia are introduced into mice. After the human globulin gene, the degree of anemia is slowed down.

For the production of animal models for gene therapy, an antisense gene method can also be used. This method is suitable for diseases caused by abnormal expression of certain genes. Specifically, the antisense DNA is injected into the fertilized egg, integrated into the genome, and the RNA complementary to the pathogenic mRNA sequence is expressed, and the pathogenic mRNA is not translated by forming the RNA duplex. Human neurotic tremor is a disease caused by a decrease in myelin basic protein (MBP). The antisense DNA of MBP was integrated into the mouse chromosomal gene, and its MBP synthesis was reduced to 50% to 70% of normal, and thus tremor occurred, and an animal model of tremor was prepared. In mice, mutants of MBP deficiency were also found to exhibit spontaneous tremors. In contrast, when MBP DNA is transferred into these mutants, a myelin basic antibody proteins is formed. When the mRNA expression reached more than 25% of the normal MBP, the symptoms disappeared, showing significant symptom recovery (treatment) and the relationship between onset and MBP expression levels, providing another way for gene therapy of transgenic animals.

Application of Transgenic Animals

The basic substance of heredity is DNA, and the gene is a DNA fragment with genetic effects on the chromosome. It can be called the genome for all genetic information stored in the complete set of chromosomes. Since the genetic composition of different species and different individuals is different, for the individual animal, the non-self genetic component belongs to the foreign gene. If the foreign gene is integrated or introduced into the animal chromosome gene, the foreign gene is Known as the transgene, this animal is a transgenic animal, such as transgenic mice service.

Transgenic animal expression systems, including exogenous genes, expression vectors and recipient cells, genomic transfer is nuclear transfer and animal cloning technology, synthetic and design genes, whole genes and even genome transgenic technology is synthetic biology.

Transfer method

The mammalian gene transfer method is to inject the reconstructed target gene (or genomic fragment) into the fertilized egg of the experimental animal by microinjection, etc., and then implant the fertilized egg into the fallopian tube of the recipient animal to develop it. A transgenic animal carrying a foreign gene.

Depending on the method and subject of foreign gene introduction, the current methods for producing transgenic animals include microinjection, retrovirus, embryonic stem cell, electric pulse, and sperm carrier.

Applications
Basic theory
Developmental Biology
Transgenic animals can be used to observe the specific expression, shutdown and regulation mechanisms of the target gene at different developmental stages of the embryo, and to understand the role of regulatory sequences (such as enhancers, promoters) in tissue-specific expression, such as human renin gene in mice. Specific expression in vivo may be related to the 5' flanking sequence of the gene. In addition, transgenic animals can be used to identify genes (including endogenous genes) and their activities during animal development, as well as to express the expression characteristics of unknown genes associated with animal development.

Genetics
Using naturally-mutated or artificially modified genes as exogenous genes, constructing transgenic animals, studying the phenotypic effects of the abnormal genes, can understand the relationship between gene structure and function, and can also be used for genomic imprinting analysis and correction of genetic defects.

Medical Research
Cardiovascular diseases
Various factors regulating cardiovascular function, such as translipoprotein and plasminogen, can be used to understand their physiological functions and functions through transgenic animals, and establish transgenics such as atherosclerosis, sudden hypertension, and venous occlusion. Animal model.

Oncology
The discovery of tumor genes is a major breakthrough in oncology research in the past 10 years, and more than 100 tumor genes such as breast cancer genes have been discovered. Experiments have shown that various vertebrates carry tumor genes, which usually do not cause cell carcinogenesis. Only under certain conditions can they be activated to cause cancer cells to proliferate and cause cancer. The establishment of transgenic animals with tumor genes can understand which tissues are sensitive to tumor targeting gene transformation activity, the relationship between tumor formation and their genes, and the influence of tumor gene growth and differentiation.

Genetic disease
Usually, a normal foreign gene is introduced into a target cell of an animal body to compensate for the defective gene, change the genetic material of the diseased cell, and perform gene therapy. Conversely, by introducing a dominant disease gene or one or even more foreign genes into an animal artificially, a transgenic animal model of hereditary diseases can be prepared to study and treat human genetic diseases. For example, Hungtington introduced the chorea gene into mice and established a chorea animal model. Redhead introduced the normal mouse MBP (myelin basic protein) gene into tremor mice, and the tremor of the mouse. The symptoms disappear.

Immunology
Babinet found that although transgenic mice produced HBsAg, there was no pathological change within 6 months, showing a persistent viral state. These results indicate that hepatocyte damage in patients with hepatitis B is not directly caused by HBVAg expression of HBV, but is caused by an immune response to viral antigens on the membrane of liver cells. Therefore, a transgenic mouse model can be used to study the relationship between immune tolerance and hepatocyte injury to explore the pathogenesis. In addition, transgenic mice production have provided new tools for studying the functions of primary and secondary major histocompatibility antigens.

Friday, April 19, 2019

History---Antibodies & Antibody Drugs

An antibody is an immunoglobulin molecule which is activated, proliferated and differentiated into plasma cells by B cells, and which is synthesized and secreted by plasma cells and has a specific amino acid sequence and can specifically bind to the corresponding antigen. The emergence of antibodies has greatly helped doctors to cure diseases, and when it comes to antibodies, they have to think about antibody drugs.

Antibody discovery
In 1953, the British biochemist Frederick Sanger successfully analyzed the chemical structure of insulin, which is also a protein, and pointed out the direction for scientists to analyze the structure of antibodies. In 1963, Edelman and Rodney Robert Porter (Sanger's first Ph.D. student) combined the results of two years of research to propose a more mature antibody molecular model. In 1969, Edelman and Porter completed an amazing achievement at the time. They successfully measured more than 1,300 amino acid sequences of antibodies and were the largest protein molecules for determining amino acid sequences at that time. In 1976, Japanese scientist Ligen Chuanjin and colleagues found that the distribution of antibody light chain genes in embryonic cells that do not produce antibodies and in the production of antibody myeloma cells revealed that the antibody genes in embryonic cells are far apart, and the antibody genes in myeloma cells. Close to the distance, this finding indicates that the germ cells are redistributed during the development of immune cells.

The emergence of humanized antibodies
The human-mouse chimeric antibody means that the constant region of the murine antibody is replaced by the constant region of the human antibody, and the variable region sequence of the murine mAb is retained to form a so-called human mouse chimeric antibody. In the mid-1980s, researchers genetically engineered murine monoclonal antibodies to produce humanized antibodies.

Although the chimeric antibody can partially solve the rejection problem of the heterologous protein, the murine variable region may still induce the HAMA reaction and interfere with the therapeutic effect. Therefore, the emergence of CDR-grafted human antibodies has brought about a turn for the development of humanized antibody drugs. Based on the chimeric antibody, the CDR-grafted antibody further replaces the mouse source with the framework region (FR), and only retains three murine-derived CDRs, and the humanity can reach more than 90%. Studies have found that FRs with support are sometimes involved in antibody binding, reducing the affinity of antigen-antibody binding.

Antibody & antibody drug
Antibody research has undergone a relatively tortuous development process. After the slow development in the early 20th century, by the advent of monoclonal antibody technology in 1975, it has been highly valued by scholars in related fields and is widely used in the fields of immunity, medicine, cancer and cell biology. The first application of monoclonal antibody therapy was in 1982, when Karr applied an anti-idiotype monoclonal antibody to the treatment of B-cell lymphoma, and the study of therapeutic antibodies soon became a hot spot in the biopharmaceutical industry.

After years of development, antibody drugs have occupied an important position in the treatment of major diseases such as malignant tumors and autoimmune diseases. The development speed is impressive, and it is the highest compound rate of biopharmaceuticals.

Antibodies have gone through more than a hundred years of history from the initial animal polyclonal to the current fully human antibodies. As antibody engineering technology continues to grow, the range of applications for antibodies is becoming more widespread. Antibody-based gene therapy has also begun to emerge as an emerging clinical treatment. And more and more new antibody drugs approved by the US FDA are born. Today, with the development of biotechnology, biologics represented by monoclonal antibody drugs will become a new trend in the development of new drugs.

Wednesday, April 17, 2019

Purification Experiment of Membrane Protein

Membrane preparation

Isolation of the plasma membrane from cells or tissues is the first step in purifying membrane proteins. Due to the lack of a biochemical method that effectively separates the membrane protein solubilized by the detergent, investing in the purification of the plasma membrane component for some time would be beneficial to the results of the subsequent steps.

Most membrane proteins are low in content, so it is important to select tissues or cell lines that are readily available in large quantities and that are highly expressed in the membrane protein of interest. Recently, there has been an increasing interest in the study of cell surface proteins as markers for identifying different cell lines or stem cells. As one of its effects, how to obtain a sufficient amount of cell membrane from a limited number of cells and to enrich the enzymatic activity of the plasma membrane marker has become a new focus in the field of membrane separation.

Preparation of cell membrane components requires disruption of tissue or cells. The most common method is to homogenize tissue or cells in isotonic sucrose buffer (0.25 md / L, p H 7 to 8) using a Douncehomogenizer. dish. Membrane proteins are relatively stable when integrated into the cell membrane. Protease may be released when cells are broken, so the inactivation caused by protein hydrolysis is the most important issue in membrane purification. Commercially available cocktails of protease inhibitors in the form of convenient tablets, such as complete protease inhibitor Cocktail (R o c h e , Indianapolis, I N ). The extracellular domain of membrane proteins is in direct contact with the oxidative environment, and most of the sulfhydryl groups are in the form of disulfide bonds, which are formed when proteins are processed in the endoplasmic reticulum. Therefore, the reducing agent may not be needed in this step. In fact, high concentrations of reducing agents alter the conformation of existing disulfide bonds, resulting in inactivation of membrane protease activity or loss of ligand binding activity. Due to the disulfide bond structure and glycosylation modification, the extracellular domain of membrane proteins is relatively resistant to protein hydrolysis. However, there are exceptions. For example, Ca~-dependent cell adhesion molecule C a d h e r m s is susceptible to protein hydrolysis when C a 2+ is removed by E D T A . In contrast, the intracellular domain that mediates membrane protein signaling is often susceptible to protein hydrolysis. For example, the insulin receptor, if there is not enough protease inhibitor in the homogenate and subsequent membrane separation steps, its receptor tyrosine kinase activity will be greatly lost.

The most common membrane separation method employs a combination of differential centrifugation and sucrose density gradient centrifugation. Due to differences in lipid and protein composition, cell membranes have different densities that allow them to be separated from other organelles. Differential centrifugation removes soluble proteins, most of the mitochondria and nuclei from the cell homogenate. The sucrose density gradient can further separate cell membranes of different densities. However, multi-step centrifugation is too lengthy and only a small fraction of the plasma membrane is obtained. Many plasma membranes are generally lost in earlier centrifugation steps. Therefore, this method is more suitable for separating cell membranes from tissues that are easier to obtain. In biochemical studies, the liver of rats is one of the tissues most commonly used to isolate the plasma membrane of cells. There have been many methods for separating different membrane components from rat liver. Neville (1%8) uses a method of homogenizing the liver in a hypotonic solution followed by a discontinuous sucrose gradient centrifugation, which is a very good method for recovering the liver plasma membrane and has been widely used.

In the case where only a small amount of tissue culture cells are used, it is necessary to increase the recovery of the plasma membrane protein without sacrificing the purity of the membrane. The affinity matrix provides a simple and rapid method of membrane purification. Conventional agarose or acrylamide affinity matrices cannot be used to separate cell membranes because they precipitate relatively high density organelles (such as nuclei). Chemically treated magnetic beads can be coupled to a variety of proteins, which has become a new form of affinity matrix. Unlike conventional agarose or acrylamide affinity matrices, magnetic beads can be easily separated from the mixture by magnets and can therefore be used to separate organelles regardless of the density of the organelles. Simply by placing the centrifuge tube containing the magnetic beads close to the magnet, the magnetic beads can be recovered in the centrifuge tube near the end of the magnet and easily separated from the mixture. Therefore, magnetic beads can be used as an alternative to centrifugation. This property has great advantages for separating the plasma membrane from other organelles. We recently purified membrane proteins from cultured epithelial cells using immobilized magnetic beads (Leeetal., 2008). This step takes advantage of the fact that some membrane proteins are glycosylated and capable of binding lectin-glycoprotein in this process, biotinylated lectin with concanavain A (ConA) and chains The streptavidin magnetic beads are combined to fix ConA to the magnetic beads. The magnetic beads with ConA are mixed with the homogenized cell lysate, and the magnetic beads are recovered at one end of the centrifuge tube to remove other organelles that are not bound to the magnetic beads. The 5' nuclease is a membrane protein whose activity is enhanced after the recovery of ConA magnetic beads compared to the total cell lysate of prostate PC-3 cells or cervical HeLa cells, indicating that the cell membrane binds to ConA magnetic beads. . One drawback of the lectin magnetic bead method is that we are unable to elute cell membranes from ConA magnetic beads using the competitive alpha-methyl mannoside. This may be because competitive sugars cannot enter the binding site between the human cell membrane and the ConA magnetic beads. Therefore, we used a detergent to dissolve the membrane protein from the ConA magnetic beads.

Solubilization of natural membrane proteins
The membrane protein is embedded in the lipid bilayer. The integral membrane protein has at least one protein sequence embedded in the cell membrane, while the peripheral protein is linked to the cell membrane by electrostatic interaction or in some cases by hydrophobic interaction. The high-salt or high-p H solution is used to dissociate the peripheral membrane proteins from the membrane (Schindler et al, 2006), such as 0•5m o / L N a C l . Since no detergent is used in this process, the peripheral membrane proteins can be purified in a similar manner to soluble proteins.

Prior to purification, the integral membrane protein needs to be solubilized from the lipid bilayer to become a separate protein. Amphipathic detergents are commonly used to solubilize integral membrane proteins from cell membranes. Decontaminants may also be classified into three types: ionic, nonionic, and zwitterionic.

After the detergent-treated cell membrane was centrifuged at 105 000 g and 4 ° C for 1 h, if the membrane protein was in the supernatant fraction, the membrane protein was considered to "dissolve" from the cell membrane. This process of detergent membrane proteins can be divided into several stages. In the first stage, the detergent binds to the cell membrane. As the detergent content increases, the detergent begins to lyse the cell membrane. A further increase in detergent content can result in the formation of a lipid/protein/detergent complex. At this time, the membrane protein is "dissolved". At this point, an additional detergent is required to "defatted Y de U pkkte" into a protein/detergent complex and a lipid/detergent complex. In general, the ratio of detergent to protein is 1 to 2 is sufficient to dissolve the membrane protein into a lipid/protein/detergent complex. A ratio of about 10 or higher will result in defatting of the complex.
(Hjelmeland, 1990). For a specific membrane protein, the best decontaminant and protein ratio of the lytic membrane protein needs to be determined experimentally.

The choice of decontaminant can be simply stated as the selection of a detergency that will work for the target protein. Non-deformable detergents can solubilize the membrane without losing it or losing its function. Among the alternative detergents, Triton X-100, sodium cholate, CHAPS, and octylglucoside are non-denatured in most cases, although they are lost during the dissolution process. Part of the activity.

The presence of detergents can affect the purification of proteins in a number of ways. Detergents can affect the detection of protein activity. For example, detergents can affect the transport activity of cell membrane transporters, while for receptors, detergents can affect their ligand binding activity. Since proteins are no longer associated with cell membranes, measuring transport activity requires recombination of soluble membrane proteins into phospholipid vesicles. Also for specific receptors, a method is required to separate the unbound ligand from the ligand-receptor complex. These requirements may limit the type of detergent used in solubilization. For example, if it is necessary to recombine the membrane into a phospholipid vesicle, a detergent with a high critical binder concentration (sodium cholate, CH A P S , octyl glucoside) should be used because they are more easily removed by dialysis.

Purification of membrane proteins
(1) Use a sufficient amount of detergent to maintain the integral membrane protein in a soluble form in the buffer and prevent protein aggregation.

(2) Protein separation methods based on protein hydrophobicity, such as phenyl-sepharose and reversed phase chromatography, may not be suitable for purification of membrane proteins, since most detergents are hydrophobic.

(3) Ionic detergents that solubilize membrane proteins, such as cholate or deoxycholate, are not suitable for ion exchange chromatography. Nonionic or facultative detergents can be used in charge-based preparation techniques, including ion exchange chromatography and preparative electrophoresis.

(4) Glycosyl-containing detergents may interfere with specific lectin chromatography, such as octylglucoside, which interferes with ConA stratification.

(5) Since the dissolved membrane protein is in the detergent micelle, the membrane protein has a larger apparent molecular mass in gel filtration. Detergents capable of forming macromolecular mass micelles, such as Trtion X-100, increase the molecular mass of the dissolved membrane protein by 60 to 100 kDa. Therefore, most proteins appear in the mass portion of the polymer, making protein separation based on molecular size difficult.

(6) The binding of membrane proteins to detergent micelles, especially detergents with large micelle size or ionic species, can mask the charge of membrane proteins. Therefore, the ability of ion exchange chromatography to separate membrane proteins may not be as good as non-membrane proteins.

(7) In general, affinity chromatography is currently the most useful and successful method for purifying integrated membrane proteins and can be used in all stages of purification. Since ion exchange chromatography is sensitive to the ionic strength of the buffer, while gel filtration requires a relatively small volume of concentrated sample, affinity chromatography can be used for purification, concentration, and salt displacement in different chromatography steps. Several commonly used affinity chromatography methods for membrane protein purification are set forth in the following sections.

Protein structure studies or in order to produce antibodies against membrane antibody proteins, it is often necessary to express and purify the recombinant membrane protein to obtain sufficient protein. Membrane is usually expressed as a mammalian cell or a cytoplasmic cell. The signal sequence is important for targeting the protein to the endoplasmic reticulum, which affects the synthesis of the protein and the post-translational modification. Therefore, the label is usually added to the end of the sequence to avoid the film target process that affects the protein. Sometimes, the signal sequence from other proteins is used to increase the efficiency of the custom membrane protein antibody.